Clinical TrialsSearch results for "eribulin mesylate"
Number of results: 18
- Recruitment status
- Title of the study
- Health Condition
- Primary sponsor
- Date of registration
Other
- A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy
- Breast Cancer
- Inoguchi Akihiro
- 2022-06-09
Completed
- A Study of Dato-DXd Versus ICC in Inoperable or Metastatic HR-positive, HER2-negative Breast Cancer
- Breast Cancer
- Inoguchi Akihiro
- 2021-11-22
Other
- study of E7389 liposomal formulation plus Nivolumab in subjects with solid tumor
- Solid Tumor (Phase 2 part: GC, EGC, SCLC)
- Eisai Co., Ltd.
- 2019-09-18
Completed
- JBCRG-M06(EMERALD)
- HER2-positive progressive-recurrent breast cancer
- Yamashita Toshinari
- 2019-03-25
Other
- Phase II trial of eribulin in patients with recurrent glioblastoma (ENIGMA)
- Glioblastoma
- National Cancer Center
- 2017-12-19
Other
- Study of E7389 Liposomal Formulation in Subjects With Solid Tumor
- Solid Tumor
- Eisai Co., Ltd.
- 2017-07-18
Other
- A phase III clinical study to compare the combination therapy of <em>eribulin mesylate</em> + trastuzumab + pertuzumab with paclitaxel or Docetaxel + trastuzumab + pertuzumab
- HER2-positive progressive-recurrent breast cancer
- Japan Breast Cancer Research Group
- 2017-06-28
Other
- A multicenter randomized phase II clinical trial with neo -adjuvant chemotherapy containing <em>eribulin mesylate</em> for triple negative primary breast cancer patients (Neo-Entrance study)
- Patients with operable primary triple-negative breast cancer without prior treatment
- Japan Breast Cancer Research Group)
- 2016-09-15
Recruiting
- A Phase II, Open-label, Multicenter, Translational Study for Biomarkers of <em>Eribulin Mesylate</em>: Evaluation of the Utility of Monitoring Epithelial-to-Mesenchymal Transition (EMT) Markers on Tumor Cells in the Malignant Plural Effusion of Patients with Metastatic Breast Cancer
- Metastatic Breast Cancer
- Shizuoka Cancer Center
- 2016-06-01
Other
- Pharmacokinetic, pharmacodynamic and biomarker study of phase I/II study of olaparib in combination with <em>eribulin mesylate</em> for patients with recurrent or metastatic triple-negative-type breast cancer
- Breast Cancer
- National Cancer Center Hospital
- 2015-08-21